Email this page: News Release
The Lancet Infectious Diseases Publishes Phase 3 Study Results Confirming Superior Rate of Sustained Clinical Response of DIFICID® (fidaxomicin) Tablets Compared to Oral Vancomycin in Adult Patients with Clostridium difficile Infection (CDI)
To (email address):
Separate multiple addresses with commas. Maximum 200 characters.
Your email address:
These email addresses will be used to email the page on your behalf and will not be used by Optimer Pharmaceuticals, Inc. for any marketing purposes.
Add a comment:
Link to page
Type in number:
This helps Optimer Pharmaceuticals, Inc. prevent automated submissions.